Cationic Tripeptide Compounds Disrupt Viral Envelopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments face challenges due to viral resistance, particularly in enveloped viruses, as mutations in viral proteins can render them resistant to existing drugs targeting these proteins, necessitating alternative therapeutic options.
Innovation Solution
Development of cationic tripeptide compounds, such as LTX-109, which exhibit antiviral activity by disrupting the viral envelope, providing a mechanism that is less susceptible to resistance development since it targets the lipid layer rather than specific viral proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral treatments target specific viral proteins, then antiviral activity is achieved, but viral resistance develops due to mutations in the targeted proteins
Solution Approach 1:
The patent extracts the target from specific viral proteins to the viral envelope lipid layer. By removing the dependency on specific protein targets and instead targeting the universal lipid envelope structure, the invention eliminates the pathway for resistance development through protein mutation while maintaining antiviral activity.
Solution Approach 2:
The patent changes the target parameter from specific protein structures to the general lipid envelope composition. This parameter shift from protein-specific to lipid-based targeting fundamentally alters the interaction mechanism, making viral mutations ineffective against the therapeutic approach.
2Ease of operation
If existing antiviral drugs are used, then treatment of viral infections is possible, but resistance to these drugs emerges over time
Solution Approach 1:
Instead of targeting viral proteins with small molecule inhibitors as conventionally done, the patent inverts the approach by using cationic peptides that target the viral envelope lipids. This inversion of the target and mechanism provides a fundamentally different therapeutic strategy that bypasses resistance issues.
3Reliability
If tripeptide compounds with cationic amino acids and lipophilic groups are designed, then disruption of viral envelope is achieved, but compound complexity increases
Solution Approach 1:
The patent applies local quality by concentrating specific functional groups (cationic amino acids and lipophilic cyclic groups) at strategic positions within the tripeptide structure. This localized functional distribution enables envelope disruption while maintaining a relatively simple overall molecular framework.
Solution Approach 2:
The tripeptide compounds function as composite structures combining cationic amino acid residues with lipophilic cyclic groups. This composite design integrates charge-based and hydrophobic-based mechanisms into a single molecular entity, achieving enhanced antiviral activity through synergistic local properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate significant antiviral activity against enveloped viruses, including SARS-CoV-2, Influenza A, and RSV, achieving high reductions in viral infectivity, thereby offering a promising alternative to existing treatments with reduced risk of resistance.
Implementation Method 1
these compounds act by disrupting the lipid layer (or envelope) of the target virus
Data Source
AI summary
The present invention provides a compound for use in the treatment of an enveloped virus infection in a subject, wherein said compound is a compound of Formula (I) as defined herein: AA-AA-AA-X-Y-Z (I). The invention further provides a method of treating an enveloped virus infection in a subject, which method comprises administering to a subject in need thereof an effective amount of a compound of Formula (I).